JP2017536397A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536397A5
JP2017536397A5 JP2017529401A JP2017529401A JP2017536397A5 JP 2017536397 A5 JP2017536397 A5 JP 2017536397A5 JP 2017529401 A JP2017529401 A JP 2017529401A JP 2017529401 A JP2017529401 A JP 2017529401A JP 2017536397 A5 JP2017536397 A5 JP 2017536397A5
Authority
JP
Japan
Prior art keywords
cancer
use according
pancreatic
fibrosis
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017529401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536397A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/063475 external-priority patent/WO2016090021A1/en
Publication of JP2017536397A publication Critical patent/JP2017536397A/ja
Publication of JP2017536397A5 publication Critical patent/JP2017536397A5/ja
Pending legal-status Critical Current

Links

JP2017529401A 2014-12-03 2015-12-02 線維症の治療方法 Pending JP2017536397A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086945P 2014-12-03 2014-12-03
US62/086,945 2014-12-03
PCT/US2015/063475 WO2016090021A1 (en) 2014-12-03 2015-12-02 Methods of treating fibrosis

Publications (2)

Publication Number Publication Date
JP2017536397A JP2017536397A (ja) 2017-12-07
JP2017536397A5 true JP2017536397A5 (enExample) 2019-01-31

Family

ID=56092404

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529401A Pending JP2017536397A (ja) 2014-12-03 2015-12-02 線維症の治療方法

Country Status (12)

Country Link
US (2) US9844552B2 (enExample)
EP (1) EP3226864A4 (enExample)
JP (1) JP2017536397A (enExample)
CN (1) CN106999482A (enExample)
AR (1) AR102871A1 (enExample)
AU (1) AU2015358503A1 (enExample)
BR (1) BR112017011897A2 (enExample)
CA (1) CA2968866A1 (enExample)
HK (1) HK1244692A1 (enExample)
MX (1) MX2017007245A (enExample)
TW (2) TW201740953A (enExample)
WO (1) WO2016090021A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103411A1 (en) 2013-10-25 2015-04-30 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
CN113694187A (zh) * 2021-07-20 2021-11-26 上海市东方医院(同济大学附属东方医院) 一种用于抑制心肌纤维化的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
WO2011133609A2 (en) * 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
ES2548414T3 (es) * 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
CA3103411A1 (en) 2013-10-25 2015-04-30 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
TW202228700A (zh) 2013-12-02 2022-08-01 美商製藥公司 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
CN105793251B (zh) 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
US9982265B2 (en) 2014-03-28 2018-05-29 Board Of Regents, The University Of Texas System Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis

Similar Documents

Publication Publication Date Title
Torres et al. Features, diagnosis, and treatment of nonalcoholic fatty liver disease
JP2015523397A5 (enExample)
JP2015536964A5 (enExample)
JP2020511414A5 (enExample)
JP2021512131A5 (enExample)
JP2016528162A5 (enExample)
JP2015007118A5 (enExample)
JP2020513745A5 (enExample)
JP2013534535A5 (enExample)
JP2015528491A5 (enExample)
NZ598145A (en) Folate-targeted diagnostics and treatment
JP2012526822A5 (enExample)
JP2013536236A5 (enExample)
JP2021518335A5 (enExample)
JP2021105005A5 (enExample)
JP2013544892A5 (enExample)
EA202090139A1 (ru) Контрастный агент для компьютерной томографии
RU2014141934A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями
RU2017124371A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина
JP2013528215A5 (enExample)
FI3630112T3 (fi) Regorafenibin ja nivolumabin yhdistelmä syövän hoidossa
RU2015139515A (ru) Комбинированное лечение
RU2017124612A (ru) Комбинация производного 6-оксо-1, 6-дигидро-пиридазона, обладающего противораковой активностью, с ингибитором рэфр
RU2015117550A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, имеющего противораковую активность, с мек ингибитором
JP2016500649A5 (enExample)